Franz J. Legat

Graz, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Journal: Allergologie select

Published: May 06, 2026

Stress in dermatology patients: A multicenter observational study of 8295 outpatients and controls from 22 European clinics.

Stress in dermatology patients: A multicenter observational study of 8295 outpatients and controls from 22 European clinics.

Journal: JAAD international

Published: December 12, 2025

Suicidal ideation in patients with skin conditions: A multicentre European study.

Suicidal ideation in patients with skin conditions: A multicentre European study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 27, 2025

Quick assessment of quality-of-life in itch: An exploratory validation of the 5-item pruritus life quality.

Quick assessment of quality-of-life in itch: An exploratory validation of the 5-item pruritus life quality.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: October 20, 2025

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 10, 2025

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.

Journal: Acta dermato-venereologica

Published: October 08, 2025

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.

Journal: BMJ open

Published: July 11, 2025

The SWITCH algorithm: An expert consensus on treat-to-target criteria for chronic prurigo.

The SWITCH algorithm: An expert consensus on treat-to-target criteria for chronic prurigo.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 19, 2025

Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.

Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.

Journal: Dermatology and therapy

Published: June 03, 2025

Predictors of treatment survival in patients with plaque psoriasis treated with phototherapy: registry analysis.

Predictors of treatment survival in patients with plaque psoriasis treated with phototherapy: registry analysis.

Journal: Skin health and disease

Published: February 28, 2025

Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study.

Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study.

Journal: The British journal of dermatology

Published: February 08, 2025

Addiction and chronic skin diseases: A Pan-European study on prevalence, associations and patient impact.

Addiction and chronic skin diseases: A Pan-European study on prevalence, associations and patient impact.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 22, 2025

Showing 1-12 of 78

Last Updated: 09/26/2026